# Flecainide

Drug · id `cardio:flecainide` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Tambocor

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

Flecainide is a medicine taken by mouth, sold as flecainide acetate, that the US label describes as an antiarrhythmic drug, a medicine for heart rhythm problems. The label read, a generic tablet label, lists for people without structural heart disease the prevention of paroxysmal supraventricular tachycardias and of paroxysmal atrial fibrillation or flutter that cause disabling symptoms. It also lists the prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that a physician judges to be life-threatening. The label says there is no evidence from controlled trials that the medicine favorably affects survival or the incidence of sudden death. It carries a boxed warning about an excess of deaths or non-fatal cardiac arrests in a trial of people who had had a heart attack.

## Technical summary

RxNorm ingredient 4441 (flecainide); the label names the salt flecainide acetate (RxNorm 42686, UNII M8U465Q1WQ, a broad match to the ingredient). MeSH descriptor D005424 is Flecainide. RxClass lists the FDA established pharmacologic class Antiarrhythmic. The label read is the Hikma Pharmaceuticals USA Inc. generic flecainide acetate tablet label, application ANDA076278, effective 2024-12-04 in openFDA; it is the only active ingredient of the product. The brand Tambocor (NDA018830) is listed in Drugs@FDA with marketing status Discontinued, and the openFDA name search for it returned no record, so no brand label was read. The other 34 openFDA flecainide labels, from manufacturers and repackagers, were not read. This page records label indications, the class, the mechanism sentence and the boxed warning on mortality only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients with asymptomatic non-life-threatening ventricular arrhythmias after a myocardial infarction, as described in a US flecainide label boxed warning

Recipient: Recipient not specified; Population: The patients of the trial known as Cardiac Arrhythmia Suppression Trial (CAST), as the boxed warning describes them: patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years earlier. The warning says how far its results apply to other groups is uncertain. The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label carries a boxed warning on mortality. It describes the trial known as Cardiac Arrhythmia Suppression Trial (CAST), in patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years earlier, and says an excessive mortality or non-fatal cardiac arrest rate was seen in patients treated with flecainide acetate compared with a matched placebo group.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: The patients of the trial known as Cardiac Arrhythmia Suppression Trial (CAST), as the boxed warning describes them: patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years earlier. The warning says how far its results apply to other groups is uncertain. The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the first statement of the label's boxed warning only. The warning goes on to give the trial's numbers, to say how far the results apply to other populations, and to describe ventricular proarrhythmic effects in atrial fibrillation or flutter; those parts are not repeated here. Other warnings, contraindications and interactions were not recorded, and no instruction is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for flecainide acetate tablets, Hikma Pharmaceuticals USA Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 4f6b78d4-8ac8-464b-bb78-ee70cbc97898 (manufacturer Hikma Pharmaceuticals USA Inc., application ANDA076278), returned on 2026-11-18. The label text is dated 2024-12-04 (effective\_time). Other openFDA records of flecainide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224f6b78d4-8ac8-464b-bb78-ee70cbc97898%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], Mortality, trial population. Retrieved 2026-11-18T21:55:08Z. Source state: Current. Version fingerprint: f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78.
     How it applies: Label passage quoted in the research quote table (LB-12).
  2. Supports: openFDA drug label record for flecainide acetate tablets, Hikma Pharmaceuticals USA Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 4f6b78d4-8ac8-464b-bb78-ee70cbc97898 (manufacturer Hikma Pharmaceuticals USA Inc., application ANDA076278), returned on 2026-11-18. The label text is dated 2024-12-04 (effective\_time). Other openFDA records of flecainide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224f6b78d4-8ac8-464b-bb78-ee70cbc97898%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], Mortality, finding. Retrieved 2026-11-18T21:55:08Z. Source state: Current. Version fingerprint: f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78.
     How it applies: Label passage quoted in the research quote table (LB-13).
  3. Supports: openFDA drug label record for flecainide acetate tablets, Hikma Pharmaceuticals USA Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 4f6b78d4-8ac8-464b-bb78-ee70cbc97898 (manufacturer Hikma Pharmaceuticals USA Inc., application ANDA076278), returned on 2026-11-18. The label text is dated 2024-12-04 (effective\_time). Other openFDA records of flecainide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224f6b78d4-8ac8-464b-bb78-ee70cbc97898%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], Mortality, comparison. Retrieved 2026-11-18T21:55:08Z. Source state: Current. Version fingerprint: f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78.
     How it applies: Label passage quoted in the research quote table (LB-14).
  4. Background: openFDA drug label record for flecainide acetate tablets, Hikma Pharmaceuticals USA Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 4f6b78d4-8ac8-464b-bb78-ee70cbc97898 (manufacturer Hikma Pharmaceuticals USA Inc., application ANDA076278), returned on 2026-11-18. The label text is dated 2024-12-04 (effective\_time). Other openFDA records of flecainide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224f6b78d4-8ac8-464b-bb78-ee70cbc97898%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T21:55:08Z. Source state: Current. Version fingerprint: f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78.
     How it applies: Effective date of the label text read, 20241204.

## Context: Patients with paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation or flutter, or life-threatening ventricular arrhythmias, as described in the US label of flecainide acetate tablets

Recipient: Recipient not specified; Population: Patients described in the indications section of the label: patients without structural heart disease who have paroxysmal supraventricular tachycardias or paroxysmal atrial fibrillation or flutter with disabling symptoms, and patients with documented life-threatening ventricular arrhythmias. The passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of flecainide acetate tablets (Hikma Pharmaceuticals USA Inc., application ANDA076278; the version dated 2024-12-04 in openFDA) describes flecainide as an antiarrhythmic drug. For patients without structural heart disease it lists prevention of paroxysmal supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia, and of paroxysmal atrial fibrillation or flutter, each when associated with disabling symptoms. It also lists prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the physician's judgment are life-threatening. It states that there is no evidence from controlled trials that flecainide acetate favorably affects survival or the incidence of sudden death.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label: patients without structural heart disease who have paroxysmal supraventricular tachycardias or paroxysmal atrial fibrillation or flutter with disabling symptoms, and patients with documented life-threatening ventricular arrhythmias. The passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's indications section also carries usage statements on chronic atrial fibrillation and on where treatment for sustained ventricular tachycardia begins; they are not recorded here. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. The brand label (Tambocor) was not read, and openFDA lists other flecainide labels with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for flecainide acetate tablets, Hikma Pharmaceuticals USA Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 4f6b78d4-8ac8-464b-bb78-ee70cbc97898 (manufacturer Hikma Pharmaceuticals USA Inc., application ANDA076278), returned on 2026-11-18. The label text is dated 2024-12-04 (effective\_time). Other openFDA records of flecainide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224f6b78d4-8ac8-464b-bb78-ee70cbc97898%22&limit=1>
     Locator: results\[0\].description\[0\], first sentence. Retrieved 2026-11-18T21:55:08Z. Source state: Current. Version fingerprint: f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for flecainide acetate tablets, Hikma Pharmaceuticals USA Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 4f6b78d4-8ac8-464b-bb78-ee70cbc97898 (manufacturer Hikma Pharmaceuticals USA Inc., application ANDA076278), returned on 2026-11-18. The label text is dated 2024-12-04 (effective\_time). Other openFDA records of flecainide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224f6b78d4-8ac8-464b-bb78-ee70cbc97898%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], indications statement. Retrieved 2026-11-18T21:55:08Z. Source state: Current. Version fingerprint: f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78.
     How it applies: Label passage quoted in the research quote table (LB-05).
  3. Supports: openFDA drug label record for flecainide acetate tablets, Hikma Pharmaceuticals USA Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 4f6b78d4-8ac8-464b-bb78-ee70cbc97898 (manufacturer Hikma Pharmaceuticals USA Inc., application ANDA076278), returned on 2026-11-18. The label text is dated 2024-12-04 (effective\_time). Other openFDA records of flecainide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224f6b78d4-8ac8-464b-bb78-ee70cbc97898%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], first bullet. Retrieved 2026-11-18T21:55:08Z. Source state: Current. Version fingerprint: f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78.
     How it applies: Label passage quoted in the research quote table (LB-06).
  4. Supports: openFDA drug label record for flecainide acetate tablets, Hikma Pharmaceuticals USA Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 4f6b78d4-8ac8-464b-bb78-ee70cbc97898 (manufacturer Hikma Pharmaceuticals USA Inc., application ANDA076278), returned on 2026-11-18. The label text is dated 2024-12-04 (effective\_time). Other openFDA records of flecainide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224f6b78d4-8ac8-464b-bb78-ee70cbc97898%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], second bullet. Retrieved 2026-11-18T21:55:08Z. Source state: Current. Version fingerprint: f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78.
     How it applies: Label passage quoted in the research quote table (LB-07).
  5. Supports: openFDA drug label record for flecainide acetate tablets, Hikma Pharmaceuticals USA Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 4f6b78d4-8ac8-464b-bb78-ee70cbc97898 (manufacturer Hikma Pharmaceuticals USA Inc., application ANDA076278), returned on 2026-11-18. The label text is dated 2024-12-04 (effective\_time). Other openFDA records of flecainide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224f6b78d4-8ac8-464b-bb78-ee70cbc97898%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], also-indicated bullet. Retrieved 2026-11-18T21:55:08Z. Source state: Current. Version fingerprint: f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78.
     How it applies: Label passage quoted in the research quote table (LB-08).
  6. Supports: openFDA drug label record for flecainide acetate tablets, Hikma Pharmaceuticals USA Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 4f6b78d4-8ac8-464b-bb78-ee70cbc97898 (manufacturer Hikma Pharmaceuticals USA Inc., application ANDA076278), returned on 2026-11-18. The label text is dated 2024-12-04 (effective\_time). Other openFDA records of flecainide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224f6b78d4-8ac8-464b-bb78-ee70cbc97898%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], survival sentence. Retrieved 2026-11-18T21:55:08Z. Source state: Current. Version fingerprint: f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78.
     How it applies: Label passage quoted in the research quote table (LB-09).
  7. Background: openFDA drug label record for flecainide acetate tablets, Hikma Pharmaceuticals USA Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 4f6b78d4-8ac8-464b-bb78-ee70cbc97898 (manufacturer Hikma Pharmaceuticals USA Inc., application ANDA076278), returned on 2026-11-18. The label text is dated 2024-12-04 (effective\_time). Other openFDA records of flecainide labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%224f6b78d4-8ac8-464b-bb78-ee70cbc97898%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T21:55:08Z. Source state: Current. Version fingerprint: f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78.
     How it applies: Effective date of the label text read, 20241204.

## Connected pages

- Flecainide is an antiarrhythmic (FDA established pharmacologic class in RxClass): Antiarrhythmic drugs (`cardio:antiarrhythmic-drugs`)
- FDA label lists prevention of paroxysmal supraventricular tachycardias associated with disabling symptoms, in patients without structural heart disease, as an indication: Supraventricular tachycardia (`cardio:supraventricular-tachycardia`) [a claim, not a settled fact; see claim `cardio:claim-fda-flecainide-label-indications` and its context]
- FDA label lists prevention of paroxysmal atrial fibrillation or flutter associated with disabling symptoms, in patients without structural heart disease, as an indication: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`) [a claim, not a settled fact; see claim `cardio:claim-fda-flecainide-label-indications` and its context]
- FDA label lists prevention of paroxysmal atrial fibrillation or flutter associated with disabling symptoms, in patients without structural heart disease, as an indication: Atrial flutter (`cardio:atrial-flutter`) [a claim, not a settled fact; see claim `cardio:claim-fda-flecainide-label-indications` and its context]
- FDA label lists prevention of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, as an indication: Ventricular tachycardia (`cardio:ventricular-tachycardia`) [a claim, not a settled fact; see claim `cardio:claim-fda-flecainide-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: 879f0366a909366cbcffbad1f6d58a31d5b6c5b3feaab4314b162b8ecfed2abd
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
